The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), or SCINTIX Biology-guided radiotherapy (BgRT) in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to quantify the health economic impact of this modality. Workflow and quality of radiotherapy planning including a collection of dosimetric data will also be analyzed.
Able to comprehend and be willing to sign an informed consent form (ICF).
Diagnosis of local, loco-regionally advanced, or metastatic malignancy for whom radiotherapy is indicated
Radiotherapy to be delivered on the RMRS X1 with IMRT, SBRT, or BgRT technique.
Absence of concurrent illness that deems radiotherapy a contraindication which will be determined by the treating radiation oncologist.
Pregnant or expecting to conceive during the study.
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with study requirements and follow-up visits.
Inability to maintain immobilization, supine position for planning and treatments.
For BgRT patients only: Known allergy to FDG
RefleXion Medical
Lead sponsor